Erwin et al., 1996 - Google Patents
A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapyErwin et al., 1996
- Document ID
- 4936778426174533511
- Author
- Erwin W
- Groch M
- Macey D
- DeNardo G
- DeNardo S
- Shen S
- Publication year
- Publication venue
- Nuclear medicine and biology
External Links
Snippet
A treatment planning program for radioimmunotherapy employing quantitative Anger camera imaging and the MIRD formalism has been designed and implemented on a clinical nuclear medicine computer. Radionuclide residence times are calculated from linear, mono …
- 238000004980 dosimetry 0 title description 12
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/103—Treatment planning systems
- A61N5/1031—Treatment planning systems using a specific method of dose optimization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01T—MEASUREMENT OF NUCLEAR OR X-RADIATION
- G01T1/00—Measuring X-radiation, gamma radiation, corpuscular radiation, or cosmic radiation
- G01T1/16—Measuring radiation intensity
- G01T1/161—Application in the field of nuclear medicine, e.g. in vivo counting
- G01T1/164—Scintigraphy
- G01T1/1641—Static instruments for imaging the distribution of radioactivity in one or two dimensions using one or several scintillating elements; Radio-isotope cameras
- G01T1/1648—Ancillary equipment for scintillation cameras, e.g. reference markers, devices for removing motion artifacts, calibration devices
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Flux et al. | The impact of PET and SPECT on dosimetry for targeted radionuclide therapy | |
| Leichner et al. | Dosimetry of 131I-labeled anti-ferritin in hepatoma: a model for radioimmunoglobulin dosimetry | |
| Sgouros et al. | Three-dimensional dosimetry for radioimmunotherapy treatment planning | |
| Gear et al. | EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for 131 I mIBG treatment of neuroendocrine tumours | |
| Beauregard et al. | Quantitative 177Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system | |
| Sgouros et al. | Three-dimensional imaging-based radiobiological dosimetry | |
| Sgouros et al. | Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components | |
| Leichner et al. | Dosimetry and treatment planning for 90Y-labelled antiferritin in hepatoma | |
| Guy et al. | RMDP: a dedicated package for 131I SPECT quantification, registration and patient-specific dosimetry | |
| Stabin | Update: the case for patient-specific dosimetry in radionuclide therapy | |
| Erwin et al. | A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy | |
| Erdi et al. | Treatment planning for radio-immunotherapy | |
| Stabin et al. | Internal dosimetry as a tool for radiation protection of the patient in nuclear medicine | |
| Bardiès et al. | Scientific developments in imaging and dosimetry for molecular radiotherapy | |
| Dewaraja et al. | Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study | |
| Liu et al. | Monte Carlo-assisted voxel source kernel method (MAVSK) for internal beta dosimetry | |
| G. Stabin | Developments in the internal dosimetry of radiopharmaceuticals | |
| Strand et al. | Radioimmunotherapy dosimetry—A review | |
| Williams | Anniversary paper: nuclear medicine: fifty years and still counting | |
| Petitguillaume et al. | OEDIPE, a software for personalized Monte Carlo dosimetry and treatment planning optimization in nuclear medicine: absorbed dose and biologically effective dose considerations | |
| Hobbs et al. | Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET | |
| Bambara et al. | Estimation of kidney and bladder radionuclide activity for patients undergoing bone scan | |
| Zanzonico et al. | Patient-specific radiation dosimetry for radionuclide therapy of liver tumors with intrahepatic artery Rhenium-188 Lipiodol | |
| Ljungberg et al. | Dose planning with SPECT | |
| Nakamura et al. | Estimation of organ cumulated activities and absorbed doses on intakes of several labelled radiopharmaceuticals from external measurement with thermoluminescent dosimeters |